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Introduction
In general terms, inhibitor promiscuity (i.e., a single compound affecting multiple protein targets) can lead to either adverse off-target effects (Peters et al., 2009) or enhanced therapeutic power (Roth et al., 2004; Keiser et al., 2009) , depending on the nature and extent of promiscuity.
In the context of drug metabolism by cytochrome P450 (CYP) enzymes, drug promiscuity has potentially important effects on the occurrence of clinically-significant drug-drug interactions (DDIs) (Atkins, 2004; Greenblatt and von Moltke, 2010) . The CYP superfamily is responsible for phase I drug metabolism of the majority of pharmaceuticals and drug candidates (Nebert and Russell, 2002; Coon, 2005) . The more CYP isoforms a given small molecule inhibits, the more likely it will be involved in DDIs with many different drugs. At the same time, metabolism of a compound by multiple isoforms provides redundancy in clearance and makes DDIs less likely.
Thus the relative promiscuity of a drug toward CYP inhibition vs. CYP metabolism might be predictive of safety. Supporting this idea, Veith et al. (2009) found that FDA-approved drugs appeared qualitatively more specific with regard to CYP inhibition than a more general set of compounds (the NIH Molecular Libraries Small Molecular Repository). Conversely, several companies are making efforts to develop isoform-specific CYP inhibitors which would be administered as adjuvants to enhance the pharmacokinetic (PK) profile of drugs that are highly susceptible to CYP metabolism (Pfizer, 2009; Tibotec Pharmaceuticals, 2009; Gilead Sciences, 2009 ). Specificity in inhibition is thus an important functional parameter, but quantitative studies aimed at correlating this specificity with physicochemical properties of different compounds are handicapped by a very significant gap: there is currently no continuous measure of drug specificity with which to draw correlations, with respect to either inhibition or metabolism. In the DMD # 34645 first part of this paper, we rectify this situation by introducing an index of inhibition promiscuity (or, equivalently, specificity) adapted from one developed to quantify catalytic promiscuity of enzymes. We apply this index to large-scale screens of CYP inhibition enabled by recent advances in automation and analytical protocols, with the goal of quantifying the specificity with which a given drug inhibits a particular CYP or CYPs.
In the second part of this paper, we use Partial Least Squares Regression (PLSR), a powerful multivariate analysis technique, to identify chemical features that correlate with inhibitory activity towards particular CYPs, as well as chemical features that correlate with non-specific inhibition of several isoforms. We provide a template for how multivariate statistical techniques such as PLSR can be applied to large-scale screens of CYP inhibition, with the goals of: 1) predicting the specificity of new drugs, and 2) predicting which isoforms are likely to be targeted by a new drug. Because CYP inhibition is a crucial contributor to clinically harmful drug-drug interactions (DDIs), a more rigorous and global approach to inhibition studies will facilitate the identification of potentially problematic PK behavior early in the drug discovery process .
We demonstrate these analytical approaches on two sets of CYP inhibition data. The first set (which we denote by 'S 64 ') consists of IC 50 values obtained for 64 commercially available pharmaceutical compounds and 6 CYP isoforms (1A2, 2C8, 2C9, 2C19, 2D6, 3A4). The second dataset (denoted 'S 469 ') consists of % inhibition values measured at a fixed inhibitor concentration measured for 469 proprietary compounds and 5 isoforms (1A2, 2C9, 2C19, 2D6, 3A4) in a cocktail format, a subset of a larger (~10000-compound) set (Zientek et al., 2008) . To ensure that we efficiently sampled the full range of inhibitory patterns in the larger set, S 469 was designed to include 194 inhibitors chosen at random from the larger set, 116 compounds that DMD # 34645 6 showed no inhibition towards any isoform, 114 compounds that were qualitatively potent and specific (>90% inhibition of any one isoform and <20% inhibition of all others), and 45 inhibitors that were qualitatively potent and promiscuous (>80% inhibition of at least 4 isoforms).
I inh : An Index of Inhibitor Specificity
Shannon-Jaynes entropy is a fundamental concept that in information theory describes the amount of information in a dataset (Shannon, 1948) , or equivalently in statistical mechanics describes the relative uniformity or "flatness" of a probability distribution (Jaynes, 1957) . If there are N possible outcomes of a given process, each with probability p i , the Shannon-Jaynes entropy of the process is given by: If only one of the outcomes is certain (i.e., has p i = 1) while all others have probability zero, then H takes the value 0. On the other hand, if all outcomes have equal probability, then H takes its maximum value of log N.
We previously proposed (Nath and Atkins, 2008a ) an index to measure catalytic promiscuity based on Shannon entropy. Here we derive an analogous index to describe the promiscuity with which a given drug inhibits a set of enzymes. Consider a set of N enzymes, such that a drug displays an inhibitory potency, denoted x i , towards enzyme i. The ratio
can be thought of as approximating the probability that the drug will inhibit enzyme i out of all the enzymes in the set. Analogous to equation 1, we can then define enzyme inhibitory promiscuity as follows: If the drug inhibits all enzymes with equal potency (i.e., is completely promiscuous), I inh = 1. If the drug inhibits only one enzyme but not any of the others (i.e., is completely specific), I inh = 0.
Two important points must be made about this proposed index. First, it is dependent on the panel of enzymes included in the calculation: just as an IC 50 or a K I is a functional parameter defined for a particular pair of enzyme and inhibitor, I inh is defined for an inhibitor and a set of enzymes.
Secondly, I inh is completely independent of an inhibitor's absolute level of potency. This critical independence enables meaningful correlations to be drawn between potency and specificity for a series of inhibitors.
The I inh index can be inverted to describe promiscuity with which a particular isoform is inhibited by a panel of compounds, or in other words, the degree to which an isoform is susceptible to inhibition by a wide range of compounds. We will call this quantity the susceptibility index of an enzyme, and denote it by I susc : Here, M is the number of compounds in the inhibitor panel, x i is the inhibitory potency of compound i and x j is the inhibitory potency of compound j. We can extend I susc to account for chemical similarities among the compounds in the inhibitor panel by weighting the index in a manner exactly analogous to our previous work (Nath and Atkins, 2008a) . We performed weighting using the 166-bit MDL Key (Durant et al., 2002) feature-based fingerprints (also called MACCS keys) as chemical descriptors, because they are commonly used and easily DMD # 34645 8 implemented. The keys consist of 166 digits that take the values '1' or '0' depending on the presence or absence, respectively, of specific chemical moieties in a given inhibitor. Admittedly, fingerprint-based approaches have limitations in that they do not explicitly account for 3-dimensional structural features as well as physicochemical characteristics such as molecular mass, hydrophobicity and charge, but they are still capable of capturing important elements of chemical similarity.
We define a weighted enzyme susceptibility index, J susc : (Merkwirth et al., 2004; Arimoto et al., 2005) in that it can be used to reconstruct a continuous range of predicted values for the variable of interest, rather than simply binning it into one of two or more categories. Compared to support vector regression, PLSR is easier to implement and interpret, and often provides similar results (Ustün et al., 2007; Shah et al., 2010) .
We have previously found the related technique PCA useful in understanding how individual probe substrates report on different regions of the functional space of single P450 isoforms (Nath and Atkins, 2008b) and also in the prediction of a compound's propensity to cause time dependent inhibition of CYP3A4 (Zientek et al., 2010) . Here we extend this approach from 
Materials and Methods
Reagents
Acetonitrile ( Downloaded from dilution pump's flow rate was 3.0 mL/min (100% A). After the analytes were focused onto the column, the dilution pump was stopped (minimal flow was maintained at 0.01 mL/min flow to prevent back flow) and the primary gradient pumps were ramped to 3.0 mL/min to initiate the gradient: 5 to 20% B from 0.0 to 0.5 min, 20 to 70% B from 0.5 to 1.2 min, 70% B from 1.2 to 1.4 min, and 70 to 5% B from 1.4 to 1.5 min. The compounds were monitored using the following The compound concentrations were estimated based on standard curves that were calculated using a weighed linear regression (1/x 2 ) of the concentration versus ratio of analyte to internal standard peak areas.
Inhibition values for compounds in S 469 were collected as previously described (Zientek et al., 2008) and similarly to the protocol above. Briefly, a single concentration inhibition assessment was conducted in polypropylene 384-well plates (Greiner Bio-One; Frickenhausen, Germany) using a Beckman Coulter Biomek® FX (Fullerton, CA). Compounds were tested in duplicate at a concentration of 3 µM. Miconazole, a broad spectrum CYP inhibitor served as a quality control, was tested at 0.015, 0.15, and 3 µM. Reactions were performed in a final volume of 50 µL/well using final concentrations of DMSO and acetonitrile organic solvents of 0.1% (v/v) and 1.0% (v/v), respectively. Each well contained human liver microsomes (0.1 mg/mL protein), substrate cocktail (40 µM S-mephenytoin, 5 µM dextromethorphan, 5 µM diclofenac, 2 µM midazolam, and 2 µM tacrine), and a NADPH regeneration system (5 mM isocitric acid, 1 mM NADP+, and 1 U/mL isocitrate dehydrogenase) in 100 mM potassium phosphate buffer (pH 7. used as an internal standard. CYP inhibition was quantitated by simultaneously analyzing the metabolites of S-mephenytoin, dextromethorphan, diclofenac, midazolam, and tacrine using LC/MS as described by Smith et al. (2007) .
Analytical Details
Entropy-based metrics such as I inh require that the definition of inhibitory potency (x i ) values that are a) higher for more potent compounds, and b) always greater than zero. For compounds in set S 64 , we define potency as x i = -log(IC 50 /100 µM), with 100 µM serving as a reference value to ensure that x i > 0. Some compounds in S 64 did not display sufficiently potent inhibition for accurate IC 50 determinations with some isoforms. We used % activity remaining at 30 µM (the highest inhibitor concentration used) as an approximate upper bound on IC 50 for these compounds. If there was no detectable loss of activity at 30 µM, we used 99.9 µM as a universal upper bound on IC 50 . As an example, we measured the IC 50 of artemisinin with respect to CYP1A2 to be 0.83 µM. Therefore, its potency towards CYP1A2 is -log(0.83/100) = 2.08.
Furthermore, its IC 50 with respect to CYP3A4 could not be measured, but the % activity remaining at 30 µM artemisinin was 56%. Therefore, its potency towards CYP3A4 is taken to be -log(56/100) = 0.11. For compounds in S 469 , we simply define potency as % inhibition achieved at an inhibitor concentration of 3 µM, with 0.01% as a lower bound on potency.
Specificity and susceptibility indices were calculated using scripts in Python and Scientific
Python (Jones et al., 2001) . PLSR was performed using a Python script adapted from a Matlab This article has not been copyedited and formatted. The final version may differ from this version. program by Abdi (2003) . All scripts are available upon request. Log D values were calculated using Pipeline Pilot (Accelrys, San Diego, CA). As shown in Fig. 1 , the inhibitors displayed a wide range of specificity, from specific inhibitors like ranolazine (which selectively inhibits 3A4) or atenolol (which selectively inhibits 2C8) to promiscuous inhibitors like clotrimazole and isradipine (which potently inhibit all six isoforms in S 64 ). Under our experimental conditions, some of the most specific compounds display weak inhibition towards a particular isoform and no detectable inhibition towards the five others; other specific inhibitors are much more potent, such as bepridil (2D6) and cyclosporin (3A4). Note that compounds displaying weak inhibition towards all six isoforms have low specificity as determined by the I inh metric.
Results
Inhibitor Specificity
We found very low correlation between inhibitor potency and specificity (1 -I inh ) for either S 64
or the randomly-chosen subset (194 compounds) of S 469 , with R 2 values of 0.044 and 0.014 respectively ( Fig. 2A-B) . To better understand the determinants of inhibitor specificity, we further correlated I inh values with heavy-atom counts (a proxy for the molecular mass of a compound), and calculated log D values (a proxy for hydrophobicity). In the case of heavy-atom counts, we found no correlation for either S 64 or S 469 (R 2 of 3×10 -5 and 3×10 -4 respectively; Fig. 2C-D). Calculated log D values also showed no statistically significant correlation with specificity for either S 64 or S 469 , with R 2 values of 0.036 and 0.019 respectively (Fig. 2E-F ).
This article has not been copyedited and formatted. The final version may differ from this version. 
CYP Susceptibility to Inhibition
An important related question is the relative susceptibility of isoforms to inhibitors: i.e., how promiscuous or specific different CYPs are in terms of how they are affected by diverse inhibitors. Table 2 shows I susc and weighted J susc calculated for all six isoforms from S 64 . The susceptibility index values for each isoform are fairly similar before and after weighting, indicating that S 64 represents a reasonably uniform sampling -i.e., the inhibitors in S 64 do not display a marked bias towards any subspace of the functional space spanned by the full set. All six isoforms have susceptibility indices within a narrow range from 0.75 to 0.85, indicating that drug-metabolizing CYPs in general are inhibited by a broad range of compounds (as might be expected a priori for promiscuous detoxification enzymes). Within the range of observed susceptibility values, CYP3A4 has the lowest J susc value, indicating that it is slightly more resistant to inhibition by diverse compounds. CYP2C8 has the highest J susc value, meaning that it is (by a small margin) the most susceptible isoform to inhibition by diverse compounds. We performed a jackknife (leave-one-out) analysis to estimate uncertainties in the susceptibility indices. Two-tailed t tests indicated that the differences, while small, are in general meaningful:
except for CYP1A2-CYP3A4 and CYP2C8-CYP2C19, the differences between each pair are significant to at least P < 0.001. In other words, susceptibility to inhibition follows the rank-order 3A4≈1A2<2C9<2D6<2C8≈2C19.
PLSR
Because global physicochemical characteristics did not display informative correlations with specificity, we turned to PLS regression to gain additional insight. The results of regression on S 64 , shown in The larger number of compounds in S 469 instead allowed us to more rigorously evaluate the accuracy of PLSR and generate a more detailed prediction matrix without overparametrizing the regression problem. We regressed S 469 against a matrix derived from 166-bit MDL keys of each inhibitor and derived an average contribution for each feature, analogous to the S 64 feature contributions shown in Table 3 . We found that the feature-based approach captured much of the This article has not been copyedited and formatted. The final version may differ from this version. Fig. 3 ) and again found a modest correlation (R 2 = 0.53) with the experimental values.
PLSR can also be used to predict specificity directly (rather than potency values for the individual isoforms), by using a data matrix of specificity values and the same MDL-derived descriptor matrix as before. Performing this procedure on all compounds from S 469 that showed detectable inhibition, we found again a good correlation (R 2 = 0.66) between measured and predicted specificity for compounds in the training set and an R 2 of 0.44 for compounds in the test set, a level of correlation that should enable prediction of the specificity with which novel drug candidates will inhibit drug-metabolizing CYP isoforms.
Discussion
Quantitative specificity measurement may lead to better choices of prototypical specific An important aspect of entropy-based metrics like I inh is that they are (by design) independent of overall potency, allowing us to test for a correlation between potency and specificity for both datasets. This is broadly important because, in different contexts, both positive (Maly et al., 2000) and negative (Ghoreschi et al., 2009 ) relationships between potency and specificity have been posited. We found essentially no correlation, indicating that under our experimental and analytical conditions, potency and specificity must essentially be considered independent quantities for drug-metabolizing CYPs. Analogous I inh -based experiments for other families of drug targets will enable a more rigorous understanding of the trade-offs between potency and specificity in different pharmacological contexts. Similarly, the lack of correlation between heavy-atom count and specificity indicates that for the compounds in our study (heavy-atom counts range from 16 to 85 for S 64 , and from 17 to 52 for S 469 ), the size of a compound does not influence its propensity for promiscuous inhibition. Furthermore, the lack of correlation between calculated log D and specificity indicates that non-specific hydrophobic interactions are neither necessary nor sufficient for promiscuous CYP inhibition. While it has been shown that aggregate formation by hydrophobic compounds can lead to non-specific interactions, promiscuous inhibition, and consequent false-positives in drug discovery contexts (Shoichet, 2006; Coan and Shoichet, 2008) , the weak negative correlations we observe indicate that aggregate-based inhibition is probably not a major contributing factor under our assay conditions. PLSR applied to feature-based chemical descriptors and CYP inhibition behavior provided much more predictive insight than the (univariate) linear regression results discussed above. It is quite DMD # 34645 probable that more complete descriptors of chemical features and structure, possibly combined with more advanced regression or machine learning techniques such as support vector machines (Merkwirth et al., 2004) or Bayesian classifiers (Arimoto et al., 2005) , would lead to increases in accuracy. This type of analysis is made possible using a continuous, quantitative measure of specificity such as the one we have presented in this work, and the simpler approach demonstrated here as a proof of principle may itself prove useful in identifying potentially problematic CYP inhibitors early in the development process.
In an extremely comprehensive high-throughput study of CYP inhibition, Veith et al. (2009) recently studied the inhibition of five CYP isoforms by a panel of almost 17000 compounds.
They classified compounds as inhibitors, activators or inactive, and then used a fingerprint-based search to identify structural features that were under-represented in active compounds and overrepresented in inactive compounds from a "biofocused" subset (i.e., drugs and drug-like molecules), as compared to a more general subset of compounds. Such features are assumed to correlate with decreased potency towards CYPs. Our analysis differs from that of Veith et al. in that we retain potency as a continuous value (rather than binning inhibitory behavior), enabling explicit predictions of inhibitory potency values for new compounds outside our training set.
Additionally, the PLSR approach effectively compares individual compounds to identify structural features correlated with increased or decreased potency, rather than comparing groups of compounds, eliminating any possibility of bias in the recovered structural features based on the assignment of compounds to the biofocused and general subsets.
Conclusions
Several aspects of drug metabolism are explored here, which concern the relative specificity of interaction between small molecules and several cytochrome P450s. It is clear that inhibitory metabolic drug interactions resulting from overlapping preferences of drugs for the various CYPs can severely limit the use of some drug combinations, while specific CYP inhibitors could improve the therapeutic power of certain highly-metabolized drugs. As a result, tools that aid in the prediction of the propensity of drugs to share metabolic or inhibitory overlap could facilitate the prediction and modulation of DDIs. Here we applied a novel metric for inhibitory specificity and partial least squares regression to explore the range of specificities for CYP isoforms among 533 common drugs or proprietary drug candidates.
The strategy laid out here succeeds in that it agrees well with qualitatively 'known' aspects of CYP inhibition: for instance, that the presence of certain functional groups on small molecules (such as triazoles and nitroaromatics) often increases inhibition for certain drug-metabolizing
CYPs. However, it provides a more rigorous and systematic framework with which to understand and quantify these correlations. Fingerprint-based regression also succeeds quantitatively in that it predicts isoform-specific activity, or inhibitor promiscuity per se, with reasonable accuracy when performed with a sufficiently large training set.
The other major finding of this work is that there is essentially no correlation between inhibitory potency and specificity, at least for drug-metabolizing CYPs. Understanding and quantifying the nature and strength of this correlation for other families of enzymes has important implications for drug design in general. Given the growing recognition of drug promiscuity (Roth et al., 2004; Keiser et al., 2009; Peters et al., 2009) in pharmacology, similar studies correlating drug potency and specificity and identifying the determinants of drug promiscuity may prove to be powerful tools for future drug design efforts.
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